

13 Jun 2021 |

# Quick Listen: Scrip's Five Must-Know Things

by **Ian Haydock**

In this week's podcast edition of Five Must-Know Things: a ground-breaking approval for Alzheimer's in the US; LAG-3 inhibitors and new Keytruda data generate excitement at ASCO; and clinical progress for another COVID-19 vaccine.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 11 June 2021, including: a ground-breaking approval for Alzheimer's in the US; LAG-3 inhibitors and new Keytruda data generate excitement at ASCO; and progress for another COVID-19 vaccine.

These and all other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#) and [TuneIn](#) - and also now on [Spotify Podcasts](#) - and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Biogen/Eisai Win On Aduhelm Approval Bet And Wager Next On Price](#)" - Scrip, 7 Jun, 2021.)

(Also see "[With Aduhelm Out Of The Gate, Biogen Focuses On Clearing Commercial Bottlenecks](#)" - Scrip, 8 Jun, 2021.)

(Also see "[ASCO Offers Glimpse Of LAG-3 Inhibitors' Potential Opportunities – And Limitations](#)" - Scrip, 7 Jun, 2021.)

(Also see "[\*Keytruda Adjuvant Kidney Cancer Data Cement The Future Of IO\*](#)" - Scrip, 6 Jun, 2021.)

(Also see "[\*Valneva Seeks Covid Vaccine Approval On AstraZeneca Head-To-Head Data Alone\*](#)" - Scrip, 4 Jun, 2021.)

[Click here to explore this interactive content online](#) ✎